# **Special Issue**

# GPCRs: Ligands and Beyond 2023

### Message from the Guest Editors

In recent years, tremendous progress has been seen in elucidating experimental structural information for Gprotein coupled receptors (GPCRs). Mainstream, pharmaceutically relevant GPCR structural information is accessible by homology models that progressively increase the structural information. This has fostered the application of structure-based drug design tools for this emerging class of drug targets. Likewise, the discovery of natural compounds and/or endogenous ligands molecules on GPCRs has remained a largely unexplored research subject. GPCR topics of interest include: i) expression; ii) signaling; iii) molecule interaction; iv) molecular dynamics; and v) docking in physiological and pathophysiological models. Therefore, considering the success of the first volume of this Special Issue, we decided to generate a sequel to support further research.

### **Guest Editors**

Dr. Erika Cione

- 1. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Cosenza, Italy
- 2. Galascreen Laboratories, University of Calabria, Cosenza, Italy

### Dr. Maria Cristina Caroleo

Department of Health Sciences, University of Magna Graecia Catanzaro, 88100 Catanzaro, Italy

### Deadline for manuscript submissions

closed (30 September 2023)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/143784

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

### Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

